Pfizer's list of patent-protected medicines is growing by leaps and bounds, but its stock price is under pressure.Pfizer (PFE 2.27%) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock.Shares of Pfizer have been beaten severely in response to sinking sales of Comirnaty, its COVID-19 vaccine, and Paxlovid, an antiviral treatment. At its beaten-down price, it offers an eye-popping 5.9% dividend yield.Pfizer has ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

JHVEPhoto A couple of weeks ago, this blog’s technician (Gary S. Morrow) shot me a message, noting that he thought Pfizer (NYSE:PFE) was putting in a longer-term bottom. The above chart, which is a monthly chart of PFE using Worden’s TC2000 Gold (and is not the chart that was sent to me), shows the stock “oversold” on a monthly basis, and not that many stocks ever get truly oversold on a monthly basis, so you can say it’s an important technical indicator when it happens. Looking at the bottom third of ...

JHVEPhoto Pfizer (NYSE:PFE) (NEOE:PFE:CA) hasn't been a favorite biopharma play due to the unsustainable Covid boost, leading to a period of sales declines. The stock appears to have hit bottom and could get a push higher from the bird flu fears, though the company is now too focused on cost cuts. My investment thesis is now slightly bullish on the stock due to the cheap valuation. Source: Finviz Hitting Bottom The key to the investing story is removing the risk of additional Covid sales downside. Pfi ...

As one of the world's largest drugmakers, Pfizer generates lots of cash it can share with investors.A vaccine and an antiviral treatment for COVID-19 made Pfizer (PFE 0.66%) a household name in recent years, but this isn't all the company sells. There are dozens of innovative medicines in its product lineup that benefit from patent-protected market exclusivity.With patents on drugs that many patients can't live without, Pfizer had no trouble distributing about $9.25 billion to its shareholders last year in ...

Going against the grain here looks like a great idea.When looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy. Companies with juicy yields are only worth investing in provided they can support their payouts. We saw just recently that even otherwise solid income stocks with incredible yields can resort to slashing their dividends; that's exactly what happened to Walgreens Boots Alliance and Medical Properties Trust.Not every high-yield stock will suffer this fate, tho ...

These are three solid contenders for your portfolio.It's hard to beat stocks when you're looking to build wealth over many years. Per the research of Wharton professor Jeremy Siegel, stocks have outperformed bonds, gold, and the dollar over more than 200 years.Bonds were the closest competitor, but stocks beat bonds over relatively shorter periods, too; over the 75 years between 1946 and 2021, stocks grew at an average annual rate of 11.3%, versus 5.8% for long-term government bonds. (The long-term annual a ...

Pfizer (PFE) announced that it is launching a new cost-restructuring program to reduce its spending. Spanning across multiple years, the program intends to reduce the company’s costs of goods sold in a multi-phased effort.The first phase of the program, which is focused on operational efficiencies, is expected to save nearly $1.5 billion by the end of 2027. Management expects to start realizing these savings next year.Pfizer expects to incur about $1.7 billion as one-time costs for the first phase of the pr ...

From a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a key level of support. PFE recently overtook the 200-day moving average, and this suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a support or re ...

Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City.Pfizer on Wednesday said it has launched a new multi-year program to reduce costs as it works to rebound from the rapid decline of its Covid business. The announcement is in addition to another $4 billion cost-cutting effort, which Pfizer announced last year as demand for its Covid vaccine and oral drug Paxlovid slumped. In a securities filing, the pharmaceutical giant said the first phase of its new program is focused on ...